Inclusion Criteria:

- Histologically or cytologically confirmed ovarian epithelial, fallopian tube, or
primary peritoneal cavity cancer

- Recurrent or metastatic disease

- Measurable disease, defined as ≥ 1 unidimensionally measurable indicator lesion ≥ 20
mm by conventional techniques OR ≥ 10 mm by spiral CT scan

- Must have received a platinum-containing chemotherapy regimen for primary disease

- Re-treatment with a platinum-based regimen required for patients who achieved a
clinical complete response (CR) to primary therapy and then had a treatment-free
interval > 12 months (i.e., platinum-sensitive) unless the patient developed a
hypersensitivity to platinum

- Patients with a treatment-free interval < 12 months do not require prior
chemotherapy for recurrent disease

- No evidence of CNS disease, including primary brain tumors or brain metastasis

- Performance status - ECOG 0-2

- More than 3 months

- WBC ≥ 3,000/mm^3

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- No history of bleeding diathesis

- SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if due to liver
metastasis)

- Bilirubin normal

- INR ≤ 1.5 (3 if receiving warfarin)

- No history of esophageal varices

- Creatinine ≤ 1.5 mg/dL

- Creatinine clearance ≥ 60 mL/min

- Urine protein < 1+

- Urine protein < 1,000 mg on 24-hour urine collection

- Urine protein:creatinine ratio < 1.0

- No arterial thromboembolic event within the past 6 months, including any of the
following:

- Transient ischemic attack

- Cerebrovascular accident

- Unstable angina pectoris

- Myocardial infarction

- No clinically significant peripheral artery disease

- No uncontrolled hypertension

- No New York Heart Association grade II-IV congestive heart failure

- No serious cardiac arrhythmia requiring medication

- No peripheral vascular disease ≥ grade 2

- Not pregnant

- No nursing during and for ≥ 3 months after study participation

- Negative pregnancy test

- Fertile patients must use effective contraception during and for ≥ 3 months after
study participation

- No history of allergic reaction attributed to compounds of similar chemical or
biological composition to study drugs (e.g., Chinese hamster ovary cell products or
recombinant humanized antibodies)

- No serious or non-healing wound, ulcer, or bone fracture

- No active infection requiring parenteral antibiotics

- No other active malignancy within the past 5 years except nonmelanoma skin cancer or
carcinoma in situ of the cervix

- No gastrointestinal tract disease resulting in an inability to take oral medication

- No significant traumatic injury within the past 28 days

- No known HIV positivity

- No prior bevacizumab

- See Disease Characteristics

- No more than 2 prior cytotoxic chemotherapy regimens for recurrent or refractory
disease (i.e., failed to achieve a clinical CR after primary therapy)

- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

- More than 4 weeks since prior radiotherapy

- No prior radiotherapy to any indicator lesion unless disease has progressed since
completion of radiotherapy

- More than 4 weeks since prior major surgical procedure or open biopsy

- More than 1 week since prior core biopsy

- No prior surgery affecting absorption

- No concurrent major surgery

- Recovered from prior therapy

- No prior vascular endothelial growth factor (VEGF) or an epidermal growth factor
receptor (EGFR) directed therapy

- No prior erlotinib

- At least 30 days since prior investigational drugs

- More than 1 month since prior thrombolytic agents

- Concurrent warfarin allowed provided the following criteria are met:

- Patient is on a therapeutic stable dose of warfarin

- INR ≤ 3

- No active bleeding or pathological condition that would confer a high risk of
bleeding (e.g., tumor invading adjacent organs or major blood vessels or varices
that are likely to bleed)

- No other concurrent investigational agents

- No other concurrent anticancer therapy